Gold bars to be exempt from tariffs, White House clarifies
Investing.com - Leerink Partners has reduced its price target on Intellia Therapeutics (NASDAQ:NTLA) to $41.00 from $42.00 while maintaining an Outperform rating on the stock. The company, currently valued at $1.2 billion, has seen its shares decline nearly 49% over the past year, with InvestingPro data indicating the stock is currently trading near its Fair Value.
The adjustment follows Intellia’s recent quarterly earnings report and subsequent management commentary during the earnings call.
Leerink Partners cited updated financial disclosures from the quarterly earnings as a factor in revising its model for the gene editing company.
The research firm also pushed back its projected timeline for the launch of Intellia’s nex-z ATTRCM therapy from late 2029 to 2030, based on management statements during the earnings call.
Despite the slight reduction in price target, Leerink Partners reiterated its Outperform rating on Intellia Therapeutics stock, indicating continued confidence in the company’s long-term prospects.
In other recent news, Intellia Therapeutics reported its second-quarter 2025 earnings, surpassing analysts’ expectations. The company posted an earnings per share (EPS) of -0.98, which was better than the forecasted -1.03. Additionally, Intellia Therapeutics reported revenue of $14.24 million, exceeding the anticipated $11.99 million. These results reflect a positive earnings surprise for the company. Despite the favorable earnings report, the stock experienced a decline. However, pre-market trading showed a slight recovery. These developments highlight the company’s recent financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.